217 related articles for article (PubMed ID: 21614589)
1. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
[TBL] [Abstract][Full Text] [Related]
2. Multiple rare variants in high-risk pancreatic cancer-related genes may increase risk for pancreatic cancer in a subset of patients with and without germline CDKN2A mutations.
Yang XR; Rotunno M; Xiao Y; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Bennett H; Graham C; Sampson JN; Malasky M; Vogt A; Zhu B; Bianchi-Scarra G; Bruno W; Queirolo P; Fornarini G; Hansson J; Tuominen R; Burdett L; Hicks B; Hutchinson A; Jones K; Yeager M; Chanock SJ; Landi MT; Höiom V; Olsson H; Gruis N; Ghiorzo P; Tucker MA; Goldstein AM
Hum Genet; 2016 Nov; 135(11):1241-1249. PubMed ID: 27449771
[TBL] [Abstract][Full Text] [Related]
3. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy.
Ghiorzo P; Pensotti V; Fornarini G; Sciallero S; Battistuzzi L; Belli F; Bonelli L; Borgonovo G; Bruno W; Gozza A; Gargiulo S; Mastracci L; Nasti S; Palmieri G; Papadia F; Pastorino L; Russo A; Savarino V; Varesco L; Bernard L; Bianchi Scarrà G;
Fam Cancer; 2012 Mar; 11(1):41-7. PubMed ID: 21989927
[TBL] [Abstract][Full Text] [Related]
4. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
[TBL] [Abstract][Full Text] [Related]
6. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
7. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations.
Lal G; Liu L; Hogg D; Lassam NJ; Redston MS; Gallinger S
Genes Chromosomes Cancer; 2000 Apr; 27(4):358-61. PubMed ID: 10719365
[TBL] [Abstract][Full Text] [Related]
8. Mutation analysis of the PALB2 cancer predisposition gene in familial melanoma.
Sabbaghian N; Kyle R; Hao A; Hogg D; Tischkowitz M
Fam Cancer; 2011 Jun; 10(2):315-7. PubMed ID: 21153565
[TBL] [Abstract][Full Text] [Related]
9. Assessment of PALB2 as a candidate melanoma susceptibility gene.
Aoude LG; Xu M; Zhao ZZ; Kovacs M; Palmer JM; Johansson P; Symmons J; Trent JM; Martin NG; Montgomery GW; Brown KM; Hayward NK
PLoS One; 2014; 9(6):e100683. PubMed ID: 24949998
[TBL] [Abstract][Full Text] [Related]
10. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations.
Goldstein AM; Struewing JP; Chidambaram A; Fraser MC; Tucker MA
J Natl Cancer Inst; 2000 Jun; 92(12):1006-10. PubMed ID: 10861313
[TBL] [Abstract][Full Text] [Related]
11. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents.
Goldstein AM; Chan M; Harland M; Hayward NK; Demenais F; Bishop DT; Azizi E; Bergman W; Bianchi-Scarra G; Bruno W; Calista D; Albright LA; Chaudru V; Chompret A; Cuellar F; Elder DE; Ghiorzo P; Gillanders EM; Gruis NA; Hansson J; Hogg D; Holland EA; Kanetsky PA; Kefford RF; Landi MT; Lang J; Leachman SA; MacKie RM; Magnusson V; Mann GJ; Bishop JN; Palmer JM; Puig S; Puig-Butille JA; Stark M; Tsao H; Tucker MA; Whitaker L; Yakobson E; ;
J Med Genet; 2007 Feb; 44(2):99-106. PubMed ID: 16905682
[TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.
Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP
Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885
[TBL] [Abstract][Full Text] [Related]
13. Associations of 9p21 variants with cutaneous malignant melanoma, nevi, and pigmentation phenotypes in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Liang X; Pfeiffer RM; Wheeler W; Maeder D; Burdette L; Yeager M; Chanock S; Tucker MA; Goldstein AM
Fam Cancer; 2010 Dec; 9(4):625-33. PubMed ID: 20574843
[TBL] [Abstract][Full Text] [Related]
14. Detection of a rare CDKN2A intronic mutation in a Hungarian melanoma-prone family and its role in splicing regulation.
Balogh K; Széll M; Polyánka H; Pagani F; Bussani E; Kemény L; Oláh J
Br J Dermatol; 2012 Jul; 167(1):131-3. PubMed ID: 22292911
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome.
Lynch HT; Brand RE; Hogg D; Deters CA; Fusaro RM; Lynch JF; Liu L; Knezetic J; Lassam NJ; Goggins M; Kern S
Cancer; 2002 Jan; 94(1):84-96. PubMed ID: 11815963
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of 9p21 deletions in UK melanoma families.
Mistry SH; Taylor C; Randerson-Moor JA; Harland M; Turner F; Barrett JH; Whitaker L; Jenkins RB; Knowles MA; Bishop JA; Bishop DT
Genes Chromosomes Cancer; 2005 Nov; 44(3):292-300. PubMed ID: 16032697
[TBL] [Abstract][Full Text] [Related]
17. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
[TBL] [Abstract][Full Text] [Related]
18. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated.
Harinck F; Kluijt I; van Mil SE; Waisfisz Q; van Os TA; Aalfs CM; Wagner A; Olderode-Berends M; Sijmons RH; Kuipers EJ; Poley JW; Fockens P; Bruno MJ
Eur J Hum Genet; 2012 May; 20(5):577-9. PubMed ID: 22166947
[TBL] [Abstract][Full Text] [Related]
19. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
20. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling.
Potrony M; Puig-Butillé JA; Aguilera P; Badenas C; Carrera C; Malvehy J; Puig S
J Am Acad Dermatol; 2014 Nov; 71(5):888-95. PubMed ID: 25064638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
